Press Releases

Date Title
Toggle Summary Aeglea Biotherapeutics Raises $44 Million in Series B Financing
-- Financing will support development of novel treatments for inborn errors of metabolism as well as therapies targeting tumor metabolism -- AUSTIN, Texas--( BUSINESS WIRE )--Aeglea Biotherapeutics, Inc., a biopharmaceutical company developing novel treatments for inborn errors of metabolism and